Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: A cocktail study with dextromethorphan and chloroguanide alone and in combination

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 6, 1999, Pages 582-588

  Tennezé, Laurent ^b   Verstuyft, Céline ^b   Becquemont, Laurent ^b   Poirier, Jean Marie ^b   Wilkinson, Grant R ^b   Funck Brentano, Christian ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; DEBRISOQUINE 4 HYDROXYLASE; DEXTROMETHORPHAN; PROGUANIL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG URINE LEVEL; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; MALE; METABOLIC INHIBITION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0009503382     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1053/cp.1999.v66.103401001     Document Type: Article

References (22)

1. 1. Küpfer A, Schmid B, Pfaff G. Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica 1986;16:421-33.
2. 2. Jacqz E, Dulac H, Mathieu H. Phenotyping polymorphinic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 1988;35:167-71.
3. 3. Vetticaden SJ, Cabana BE, Prasad VK, Purich ED, Jonkman JH, de Zeeuw R, et al. Phenotypic differences in dextromethorphan metabolism. Pharm Res 1989;6: 13-9.
4. 4. Funck-Brentano C, Thomas G, Jacqz-Aigrain E, Poirier JM, Simon T, Béréziat G, et al. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exp Ther 1992;263: 780-6.
5. 5. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76.
6. 6. Brockmoller J, Rost KL, Gross D, Schenkel A, Roots I. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R-and S-mephenytoin and comparison with the intron4/exon5 G→A-splice site mutation. Pharmacogenetics 1995;5:80-8.
7. 7. Funck-Brentano C, Bosco O, Jacqz-Aigrain E, Keundjian A, Jaillon P. Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans. Clin Pharmacol Ther 1992;51:507-12.
8. 8. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM. The activation of the biguanide anti-malarial proguanil co-segregates with the mephenytoin oxidation polymorphism: a panel study. Br J Clin Pharmacol 1991;31:689-92.
9. 9. Partovian C, Jacqz-Aigrain E, Keundjian A, Jaillon P, Funck-Brentano C. Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans. Clin Pharmacol Ther 1995;58:257-63.
10. 10. Funck-Brentano C, Becquemont L, Leneveu A, Roux A, Jaillon P, Beaune P. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther 1997;280:730-38.
11. 11. Schellens JHM, Van der Wart JHF, Brugman M, Breiner DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. J Pharmacol Exp Ther 1989;249:638-45.
12. 12. Crom WR, SL Webster, Bobo L, Teresi ME, Relling MV, Evans WR. Simultaneous administration of multiple model substrates to assess hepatic drug clearance. Clin Pharmacol Ther 1987;41:645-50.
13. 13. Kupfer A, James R, Carr K, Branch R. Analysis of hydroxylated and demethylated metabolites of mephenytoin in man and laboratory animals using gas-liquid chromatography and high-performance liquid chromatography. J Chromatogr 1982;232:93-100.
14. 14. Meier UT, Kronbach T, Meyer UA. Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Anal Biochem 1985; 151:286-91.
15. 15. East T, Dye D. Determination of dextromethorphan and metabolites in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1985;338:99-112.
16. 16. Edstein MD. Simultaneous measurement of proguanil and cycloguanil in human plasma by high performance liquid chromatography. J Chromatogr 1986;380:184-9.
17. 17. Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM. The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol 1990;30:593-8.
18. 18. Basci NE, Bozkurt A, Kortunay S, Isimer A, Sayal A, Kayaalp SO. Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population. Br J Clin Pharmacol 1996;42:771-3.
19. 19. Jones DR, Gorski JC, Hamman MA, Hall SD. Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity. J Chromatogr B Biomed Appl 1996 ;678:105-11.
20. 20. Zhang Y, Blouin RA, McNamara PJ, Steinmetz J, Wedlund PJ. Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 1991;31:350-52.
21. 21. Jones DR, Gorski C, Haehner BD, O'Mara EM, Hall SD. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Clin Pharmacol Ther 1996;60:374-84.
22. 22. Ducharme J, Abdullah S, Wainer IW. Dextromethorphan as in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl 1996;678:113-28.